In the latest trading session, 1.58 million Can-Fite Biopharma Ltd ADR (AMEX:CANF) shares changed hands as the company’s beta touched 1.33. With the company’s most recent per share price at $1.70 changing hands around $0.05 or 3.03% at last look, the market valuation stands at $17.36M. CANF’s current price is a discount, trading about -175.88% off its 52-week high of $4.69. The share price had its 52-week low at $1.29, which suggests the last value was 24.12% up since then. When we look at Can-Fite Biopharma Ltd ADR’s average trading volume, we note the 10-day average is 45540.0 shares, with the 3-month average coming to 110.29K.
Analysts gave the Can-Fite Biopharma Ltd ADR (CANF) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended CANF as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Can-Fite Biopharma Ltd ADR’s EPS for the current quarter is expected to be 0.
Can-Fite Biopharma Ltd ADR (AMEX:CANF) trade information
Instantly CANF is in green as seen in intraday trades today. With action 9.68%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 4.62%, with the 5-day performance at 9.68% in the green. However, in the 30-day time frame, Can-Fite Biopharma Ltd ADR (AMEX:CANF) is 11.11% up. Looking at the short shares, we see there were 0.26 million shares sold at short interest cover period of 2.39 days.
The consensus price target for the stock as assigned by Wall Street analysts is 10, meaning bulls need an upside of 83.0% from its recent market value. According to analyst projections, CANF’s forecast low is 10 with 10 as the target high. To hit the forecast high, the stock’s price needs a -488.24% plunge from its current level, while the stock would need to soar -488.24% for it to hit the projected low.
Can-Fite Biopharma Ltd ADR (CANF) estimates and forecasts
Year-over-year growth is forecast to reach -32.71% down from the last financial year.
Consensus estimates given by 2 financial analysts project the company’s revenue in the current quarter to hit an average of 150k. 2 analysts are of the opinion that Can-Fite Biopharma Ltd ADR’s revenue for the current quarter will be 150k. The company’s revenue for the corresponding quarters a year ago was 196k and 196k respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -23.47%. The estimates for the next quarter sales put growth at -23.47%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 48.75%. The 2025 estimates are for Can-Fite Biopharma Ltd ADR earnings to increase by 59.37%.
